The value of 18F-FDG-PET/CT imaging for sinonasal malignant melanoma

Eur Arch Otorhinolaryngol. 2012 Jan;269(1):127-33. doi: 10.1007/s00405-011-1664-1. Epub 2011 Jun 29.

Abstract

The aim this study was to evaluate imaging findings using position emission tomography (PET) in combination with computed tomography (CT) and 18F-fluorodeoxyglucose ((18)F-FDG) in sinonasal malignant melanoma (SNMM) of the head and neck in a retrospective analysis of a consecutive cohort of patients. (18)F-FDG-PET/CT examinations were performed for initial staging and compared with CT or magnetic resonance tomography (MRI), and (18)F-FDG-PET alone. Medical records were reviewed retrospectively with regard to the location and the size of the tumor. Furthermore, locoregional and distant metastases with a consecutive change in therapy detected by (18)F-FDG-PET/CT were assessed. Ten patients suffering from sinonasal malignant melanoma were staged and followed by (18)F-FDG-PET/CT imaging. A total of 34 examinations were obtained. (18)F-FDG-PET/CT depicted all primary tumors adequately. Aside from one cerebral metastasis all regional and distant metastases were truly identified by using this method. In summary, if available, (18)F-FDG-PET/CT is a valuable imaging modality for staging and re-staging sinonasal malignant melanoma to evaluate expansion of the primary tumor, locoregional disease, and distant metastases.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Ethmoid Sinus
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Maxillary Sinus Neoplasms / diagnostic imaging
  • Melanoma / diagnostic imaging*
  • Middle Aged
  • Multimodal Imaging*
  • Nasal Cavity
  • Nose Neoplasms / diagnostic imaging*
  • Paranasal Sinus Neoplasms / diagnostic imaging*
  • Positron-Emission Tomography*
  • Radiopharmaceuticals*
  • Tomography, X-Ray Computed*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18